These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21502040)

  • 21. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.
    Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2015; 14(10):1313-29. PubMed ID: 26289975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuated influenza virus vaccines with modified NS1 proteins.
    Richt JA; García-Sastre A
    Curr Top Microbiol Immunol; 2009; 333():177-95. PubMed ID: 19768406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of the use of animals in the development and control of biological products.
    Lancet; 1985 Oct; 2(8460):900-2. PubMed ID: 2864618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review.
    Boyce TG; Poland GA
    Biomed Pharmacother; 2000 May; 54(4):210-8. PubMed ID: 10872719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell substrates. Their use in the production of vaccines and other biologicals. Past achievements - future expectations.
    Meyer HM
    Adv Exp Med Biol; 1979; 118():1-5. PubMed ID: 495259
    [No Abstract]   [Full Text] [Related]  

  • 26. Developing cell culture-derived pandemic vaccines.
    Barrett PN; Portsmouth D; Ehrlich HJ
    Curr Opin Mol Ther; 2010 Feb; 12(1):21-30. PubMed ID: 20140813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New opportunities for development of safe, effective live virus vaccines.
    Chanock RM
    Yale J Biol Med; 1982; 55(3-4):361-7. PubMed ID: 6295011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testing considerations for novel cell substrates: a regulatory perspective.
    Khan AS
    PDA J Pharm Sci Technol; 2010; 64(5):426-31. PubMed ID: 21502046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cells.
    Fischer WA; King LS; Lane AP; Pekosz A
    Vaccine; 2015 Aug; 33(36):4495-504. PubMed ID: 26196325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ICH guidelines and PhEur monographs on derivation and characterisation of cell substrates used for production of biotechnological/biological products. International Conference on Harmonisation.
    Dobbelaer R
    Dev Biol Stand; 1999; 98():159-65; discussion 167. PubMed ID: 10494969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.
    Rudenko L; Yeolekar L; Kiseleva I; Isakova-Sivak I
    Vaccine; 2016 Oct; 34(45):5436-5441. PubMed ID: 27593158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Live influenza vaccines (author's transl)].
    Gerth HJ
    MMW Munch Med Wochenschr; 1977 Jun; 119(24):821-4. PubMed ID: 407467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The development and use of vaccines based on studies of virus substructures.
    Rubin BA; Tint H
    Prog Med Virol; 1975; 21():144-57. PubMed ID: 1208876
    [No Abstract]   [Full Text] [Related]  

  • 34. Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine.
    Lee YH; Jang YH; Seong BL
    Virology; 2017 Apr; 504():73-78. PubMed ID: 28157547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vaccines: from seed virus to approval].
    Bruhn C
    Dtsch Med Wochenschr; 2009 Nov; 134(48):p44. PubMed ID: 19941270
    [No Abstract]   [Full Text] [Related]  

  • 36. Progress toward a live attenuated human hepatitis A virus vaccine.
    Hilleman MR; Provost PJ; Buynak EB; McLean AA
    Dev Biol Stand; 1983; 54():433-40. PubMed ID: 6317494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
    Girard MP; Katz J; Pervikov Y; Palkonyay L; Kieny MP
    Vaccine; 2010 Oct; 28(42):6811-20. PubMed ID: 20659520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
    Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
    Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007.
    Knezevic I; Stacey G; Petricciani J;
    Biologicals; 2008 May; 36(3):203-11. PubMed ID: 18218325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of methods used for detection of mycoplasma contamination in cell cultures, sera, and live-virus vaccines.
    Benisheva T; Sovová V; Ivanov I; Opalchenova G
    Folia Biol (Praha); 1993; 39(5):270-6. PubMed ID: 8206173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.